` MRNS (Marinus Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

MRNS
vs
S&P 500

Over the past 12 months, MRNS has significantly outperformed S&P 500, delivering a return of +139% compared to the S&P 500's +14% growth.

Stocks Performance
MRNS vs S&P 500

Loading
MRNS
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MRNS vs S&P 500

Loading
MRNS
S&P 500
Difference
www.alphaspread.com

Performance By Year
MRNS vs S&P 500

Loading
MRNS
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Marinus Pharmaceuticals Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Marinus Pharmaceuticals Inc
Glance View

Market Cap
30.4m USD
Industry
Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 113 full-time employees. The company went IPO on 2014-07-31. The firm is focused on the development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. The Company’s lead product candidate is ZTALMY (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD), which is developed for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD). Ganaxolone is a methylated analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone acts at both synaptic and extrasynaptic gamma-aminobutyric acid type A (GABAA) receptors, a target known for its anti-seizure, antidepressant, and anxiolytic potential.

MRNS Intrinsic Value
2.29 USD
Undervaluation 76%
Intrinsic Value
Price
Back to Top